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Objectives: Data generated from three similar in situ caries crossover studies presented the 
opportunity to conduct a pooled analysis to investigate how dentifrice formulations with different 
fluoride salts and combinations at concentrations of 1400–1450 ppm F, different abrasive systems and 
in some cases, carbomer (Carb), affect enamel caries lesion remineralization and fluoridation. 
Methods: Subjects continuously wore modified partial dentures holding two gauze-covered partially-
demineralized human enamel specimens for 14 days and brushed 2×/day with their assigned 
dentifrice: Study 1: sodium fluoride (NaF)/Carb/silica, NaF/silica, NaF+MFP/chalk; Study 2: 
NaF/Carb/silica, NaF+MFP/dical, amine fluoride (AmF)/silica; Study 3: NaF/Carb/silica, NaF+ 
stannous fluoride(SnF2)/silica/hexametaphosphate (HMP). All studies included Placebo (0 ppm F) 
and/or dose-response controls (675 ppm F as NaF [675F-NaF]) ±Carb. Specimens were evaluated for 
percentage surface microhardness recovery (SMHR) and enamel fluoride uptake (EFU).  
Results: All 1400–1450 ppm F dentifrices except NaF+SnF2/silica/HMP provided significantly 
greater lesion remineralization than Placebo (p<0.0001): differences in SMHR ranged from 17.46% 
(NaF+MFP/dical) to 26.66% (AmF/silica). For EFU (back-transformed log EFU), all 1400–1450 ppm 
F dentifrices gave significant fluoride uptake compared to Placebo (p<0.0001): increases in EFU 
ranged from 4.95 μg F/cm2 (NaF+SnF2/silica/HMP) to 16.32 μg F/cm2 (NaF/carb/silica). Dentifrices 
containing NaF or AmF as sole fluoride source provided the greatest remineralization and 
fluoridation; Carb addition did not alter fluoride efficacy; some excipients appeared to interfere with 
the cariostatic action of fluoride. Treatments were generally well-tolerated with ≤4 treatment-related 
adverse events per study.  
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Conclusion: Commercially available fluoride dentifrices varied greatly in their ability to remineralize 
and fluoridate early caries lesions.  
Clinical significance:  
Fluoride dentifrices are the most impactful anticaries modality worldwide. While clinical caries trials 
have not consistently shown the superiority of one formulation over another, these findings using a 
sensitive in situ caries model indicated that dentifrices containing NaF or AmF as the sole fluoride 
source provided the greatest remineralization and fluoridation benefits.     
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Introduction 
It is generally agreed that the anticaries effect of fluoride is predominantly by decreasing the rate of 
enamel demineralization and enhancing the rate of remineralization [1–3]. However, different 
formulations of fluoride dentifrices may not have the same anticaries efficacy potential [4]. There has 
been a controversy over the relative merits of sodium fluoride (NaF) versus sodium 
monofluorophosphate (MFP), with published reviews reaching different conclusions from basically 
the same clinical studies [5,6]. Not only can different fluoride salts have intrinsically different 
anticaries activities, but the formulation environment of the fluoride species can affect its delivery to 
the oral cavity and its ability to interact with enamel in vivo [4]. Furthermore, other dentifrice 
ingredients may positively or negative impact the caries process by directly inhibiting 
demineralization by offering surface protection or by interfering with remineralization.  
To examine this further, a series of three studies were carried out using an in situ caries model to 
evaluate the efficacy of a dentifrice where carbomer (high molecular weight copolymer of acrylic acid 
crosslinked with a polyalkenyl polyether) had been added to NaF as a possible aid to increase 
bioavailability of fluoride compared to a variety of commercially available dentifrice formulations. 
These dentifrices contained fluoride from a number of different sources (NaF, MFP, stannous fluoride 
[SnF2], amine fluoride [AmF]) and combinations thereof. The efficacy of these was compared to a 
variety of dose-response control dentifrices including low fluoride dentifrices (675 ppm F) and 
fluoride-free dentifrices. 
Clinical studies are limited in regard to how many treatment and control groups can be compared. 
Here we present a pooled analysis of three studies whose similar designs present a unique opportunity 
to compare the in situ remineralization performance of several commercially available products in a 
well-characterized model. The three studies carried out here were compared using a network meta-
analysis (NMA) technique applied to pooled data. Of note, this is not intended to be a full meta-
analysis, as comparison was only within the three studies reported herein. The in situ caries model 
involving partial denture appliances [7] with partially demineralized enamel specimens used in these 
studies to evaluate enhancement of net remineralization has been validated based on response to a 
variety of different dentifrice fluoride concentrations [3,8,9]. This model is advantageous as fluoride 
is delivered in the presence of physiologically secreted saliva and there are intermittent cycles of 
demineralization and remineralization during the experimental period as with the natural caries 
process. The in situ model system is used with the surface microhardness (SMH) test as the primary 
outcome measure [3,7,9–14]. Here, the hardness of sound enamel is measured and compared with the 
hardness of enamel after exposure to an in vitro acid challenge and then after intra oral exposure, 
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simulating the caries process [3]. The in situ model has also been applied to measure fluoride uptake 
from enamel specimens (enamel fluoride uptake: EFU) [3,9].  
 
Materials and Methods 
The three studies followed a similar single center, randomized, examiner-blind, reference-controlled 
crossover design. They were undertaken as part of an Investigational New Drug (IND) program (IND 
75222), with the protocols reviewed and approved by the IUPUI/Clarian Institutional Review Board 
(Study 1: IRB# 0803-14; Study 2: IRB# 0809-15; Study 3: IRB# 0910-29). All studies were 
conducted at the Oral Health Research Institute (OHRI), Indianapolis, IN, USA with subjects selected 
from the OHRI’s IRB approved database of previous research subjects, if suitable, or recruited from 
the area. Prior to study initiation all subjects gave informed consent in accordance with the 
Declaration of Helsinki. Details of these studies and results can be found at ClinicalTrials.gov 
(NCT00708097, NCT01005966, NCT01128946). There was one amendment, to Study 3 only, an 
administration change that did not affect study procedure or outcomes. 
Clinical procedures 
All studies followed the same protocol with only minor variations, as noted. At the screening visit 
(Visit 1), demographic details, medical history and concomitant medications were recorded followed 
by oral soft tissue (OST) and oral hard tissue examinations. Study entry criteria included: healthy 
volunteers aged 18–80 years with a normal saliva flow rate (unstimulated: ≥0.2 mL/minute; 
stimulated: ≥0.8 mL/minute) who wore a removable mandibular partial denture able to be adjusted to 
hold enamel test specimens and lived in the Indianapolis, IN area (with a fluoridated water supply of 
approximately 1 ppm). Subjects could not be taking fluoride supplements or using fluoride 
mouthrinse and could not have any clinically significant/relevant abnormalities of medical history or 
physical examination including current active caries or periodontal disease that could have 
compromised the study or the subject’s health. Exclusion criteria included: pregnant; breast feeding; 
intolerance to any study material; currently taking antibiotics or had taken antibiotics within 2 weeks 
prior to screening; participation in another clinical study or receipt of an investigation drug within 30 
days of screening. 
At Visit 2, 2–3 days before the start of the first treatment period, subjects received a prophylaxis and 
their partial denture was prepared for enamel specimen placement. They then brushed at home twice-
daily with a supplied fluoride-free dentifrice until Visit 3. Eligible subjects were assigned treatments 
in an order according to a randomization sequence generated by the Biostatistics and Data 
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Management department of GSK Consumer Healthcare (GSKCH). Details of the test dentifrices can 
be found in Table 1, including fluoride source and concentration, abrasive, surfactant and viscosity 
and rheology modifiers. Test dentifrices were supplied in plain white 100 ml tubes; commercially 
sourced dentifrices were supplied overwrapped with opaque white vinyl to aid in blinding participants 
and site staff to dentifrice type.  
At the start of each treatment period, two partially demineralized enamel specimens covered with 
Polyester Knit Fabric (Item# 401628, Impra, Tempe, USA) to encourage plaque formation [7] were 
placed in the buccal flange of the subject’s partial denture. Subjects performed their first brushing 
under site supervision where they applied a full ribbon (Studies 1 and 2) or 1.5 ±0.1 g (Study 3) of 
dentifrice to a wet toothbrush and brushed their natural teeth for one timed minute, taking care not to 
brush the enamel specimens, then rinsed for 10 seconds with 10 mL (Studies 1 and 2) or 15 mL 
(Study 3) water. Subjects continued the study brushing/rinsing regimen at home twice daily for 14 
days, recording brushing on a supplied diary card that was used to check compliance. During the 
treatment period subjects wore their partial denture 24 hours a day except when cleaning it with water. 
The combination of the fabric-covered specimens and the subjects’ normal diet provided a cariogenic 
environment simulating the caries process [3].   
After the 14-day study period, enamel specimens were removed and stored until analyzed. To control 
for carry-over effects there was a 7-day wash-out period between treatments during which subjects 
followed their usual dental hygiene regimen for at least 4 days, followed by a 2–3 day lead-in period. 
During this time the partial denture was re-fitted with new specimens and the OST examination, 
eligibility check, prophylaxis, and brushing procedure above was repeated. This sequence was 
continued until all subjects had used all dentifrices within their respective study. 
Enamel specimen preparation 
Specimens obtained from human permanent teeth were used as the hard tissue study substrate and 
were prepared as previously described [20] such that each had an enamel surface with a central 
minimum flattened and polished area of 3×3 mm. For SMH testing, five baseline indentations 100 μm 
apart were placed in the center of each prepared enamel specimen using a Knoop diamond under a 50 
g load. Only specimens with mean baseline indentation lengths of 43 ±3 μm were accepted. Before 
placement, the enamel specimens were partially demineralized, to simulate early carious lesions, 
using a modification of the method described by White [21]. The modification involved decreasing 
the demineralization time from 96 h to 24 h. SMH testing was repeated with five indentations placed 
to the left of the baseline indentations; only enamel specimens with mean indentation lengths of 120 
±20 μm after demineralization were used. Specimens were sterilized using ethylene oxide gas before 
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insertion into the subjects’ partial dentures where they were mounted such that the enamel surface was 
flush with the surface of the buccal flange.  
Assessment of enamel remineralization 
Changes in mineral status of partially-demineralized enamel specimens were evaluated with SMH 
testing after 14 days intraoral exposure by placing five indentations 100 μm to the right of the baseline 
indentations. The extent of remineralization, SMH Recovery (SMHR), was calculated as (D2-R/D2-
B)×100%, where D2 = indentation length (μm) after in vitro demineralization; R = indentation length 
(μm) after intra-oral exposure; B = baseline indentation length (μm) [10]. 
Assessment of fluoride bioavailability in enamel 
Fluoride availability of the partially demineralized enamel specimens was carried out after 14 days of 
intraoral exposure by a microdrill enamel biopsy technique (four cores per specimen) [22]. The 
diameter of the drill hole was determined using a calibrated microscope interfaced with an image 
analysis system. Enamel fluoride uptake (EFU) was calculated based on the amount of fluoride 
divided by the volume of the enamel cores and expressed as μg F/cm3 (Studies 1 and 2) or divided by 
the area of the enamel cores and expressed as μg F/cm2 (Study 3).  
Statistical analysis 
In Study 1, Study 2 and Study 3 respectively, 57, 65 and 85 subjects were planned to be randomized 
such that sample sizes of 52, 44 and 72 completed subjects respectively would have 90% (first two 
studies) and 80% (third study) power at the 0.05 significance level, using two-sided testing, to detect a 
respective mean difference of 9.0%, 6.5% and 5.0% in SMHR (with within subject standard deviation 
of the paired differences of 19.32%, 12.89% and 14.90% respectively, taken from GSKCH held data). 
Each of the individual studies were analyzed using ANOVA techniques with factors for treatment and 
study period with subject as a random effect. The pooled analysis of the studies individual subject 
data were compared using principles of NMA technique [17,18] using analysis of variance (ANOVA) 
methods. The safety population included all randomized subjects who used at least one of the 
treatment dentifrices then had at least one safety assessment. The intent-to-treat (ITT) population 
included all randomized subjects who had used at least one dose of study treatment and provided at 
least one SMH measurement leading to a SMHR value. The per protocol (PP) population included all 
randomized subjects who had SMH or EFU values and had no major protocol deviations. All three 
studies used the PP population as the primary population for analysis hence this pre-defined 
population was used in the NMA. 
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Efficacy variables of interest were mean SMHR and mean EFU. For SMHR calculation, for each 
subject the mean of each series of indentations was taken within each enamel block then the mean of 
the two blocks was taken. EFU was calculated taking the mean of the two enamel blocks. If a subject 
was missing an enamel block, data from the remaining block was used alone. As EFU values were 
reported as drill hole volume (µg F/cm3) for Studies 1 and 2 but as area (µg F/cm2) for Study 3, both 
with a drill hole depth of 100 µm, Study 1 and 2 values were multiplied by 0.01 so that all were 
expressed as area measures for analysis. 
For each variable, the primary objective was to investigate the effect of each treatment compared with 
NaF/carb/silica and dose response control (675F-NaF). SMHR and EFU were analyzed separately 
using an analysis of covariance (ANCOVA) model including subject as a random effect, re-coded 
treatment group, study and period nested within study as factors. A repeated subject effect grouped by 
study and treatment was also fitted into the model. The Tukey adjustment method was used to control 
for the alpha level for multiple treatment comparisons. No adjustment for multiple comparisons was 
used in the analysis of the individual studies, as a primary objective was pre-defined in each of the 
single studies. 
The ANCOVA assumptions were checked for both endpoints and considered to be sufficiently 
satisfied for SMHR. For EFU, the assumption of homoscedasticity of residuals was violated and data 
was transformed using log transformation, after which the ANCOVA model assumptions were 
satisfied. Adjusted means from the analysis were back transformed to geometric means; treatment 
ratios were back transformed to treatment differences. Approximate 95% confidence limits were 
constructed for the back transformed treatment differences using the 95% confidence limits of the log 
ratios. The following equation was used in the calculation of the back transformed treatment 
differences: Test-Reference = exp[ln(Test/Reference)] × Reference-Reference, where Reference = 
adjusted geometric mean of NaF/carb/silica or 675F-NaF; ln(Test/Reference) = adjusted log treatment 
ratio of the corresponding comparison. All analyses were conducted using the PROC MIXED 
procedure in SAS® software Version 9.2 (SAS Institute Inc., Cary, NC, US). 
The assessment of safety and tolerability were based on the safety profiles of the test treatments 
relative to Placebo with respect to treatment-emergent OST abnormalities and adverse events reported 
by subjects following the use of study treatments. 
 
Results 
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The trial profile and baseline characteristics of all subjects are described in Figure 1 and Table 2. 
From the total number of randomized subjects, 202 (98.5%) were included in the PP population for 
the pooled analysis: 57 (100%) from Study 1, 63 (96.9%) from Study 2 and 82 (98.8) from Study 3. 
Overall, subjects mean age at enrollment was 65.4 (SD=9.69) years and 59.9% were female. Study 1 
took place between April 2008–August 2008; Study 2 between October 2008–March 2009; Study 3 
between November 2009–April 2010.  
The network diagram shown in Figure 2 shows how the eight treatments are connected via the three 
studies. This network shows that out of the 8C2 = 28 possible head-to-head comparisons, these studies 
cover 20 (71%). The figure indicates the eight missing head-to-head comparisons. So, the network is 
well represented in terms of at least one head-to-head direct comparison. If the network was fully 
connected and optimized via the three studies, then there would be 3 x 8C2 = 84 comparisons. In the 
network the studies represent 5C2+5C2+4C2 = 28 comparisons, as such, the network is 28/84 = 33% 
fully represented. Overall the network is fairly well-connected, but at one third of the full optimum. 
The carbomer and 675 NaF treatments were present in all three studies and act as good anchor 
reference points. 
Results from the individual studies can be found in Supplemental Data Tables 1–4. 
SMHR (Table 3, Figures 3–7) 
With higher mean values, the NaF/carb/silica group was significantly different from NaF+MFP/dical, 
NaF+SnF2/silica/HMP, 675F-NaF and Placebo groups, with no difference compared to the other 
active dentifrices (Figure 5). The 675F-NaF group also had a statistically significant lower mean 
SMHR than the NaF/silica and AmF silica groups, but was significantly higher than the Placebo and 
NaF+SnF2/silica/HMP groups (Figure 6). Except for NaF+SnF2/silica/HMP, all other treatments were 
significantly different from the Placebo group, favoring the active dentifrices. The 
NaF+SnF2/silica/HMP group had a significantly lower mean SMHR compared to all the other active 
treatments (Table 3). Figure 7 shows the SMHR values from each of the studies and from the pooled 
analysis across the dentifrices investigated in the pooled analysis. The plot shows a very consistent 
effect from the individual studies and hence when pooled. 
EFU (Table 4, Figures 8–12) 
The NaF/Carb/silica group was significantly different, in its favor, from all but the NaF/silica and 
AmF/silica groups (Figure 10). The 675F-NaF group was numerically near the mid-range of all 
dentifrice groups, significantly different from both the higher values of the NaF/carb/silica, NaF/silica 
and AmF/silica, and the lower values of the NaF+SnF2/silica/HMP and Placebo groups (Figures 10 
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and 11). All other groups were also significantly higher than the Placebo group (Table 4). With the 
lowest EFU value of the active treatments, the NaF+SnF2/silica/HMP group was significantly 
different from all other groups (Table 4). Figure 12 shows the EFU values from each of the studies 
and from the pooled analysis across the dentifrices investigated in the pooled analysis.  Again, there 
are consistent effects from the individual studies and also when pooled. 
Safety Results (Table 5) 
In Study 1, 24 (42.1%) subjects reported 38 treatment emergent adverse events (TEAEs) with three of 
them deemed treatment-related (TR-TEAEs). In Study 2, respective figures were 35 (53.8%) subjects, 
55 TEAEs, four TR-TEAEs and, in Study 3, 40 (48.2%) subjects, 68 TEAEs, three TR-TEAEs. No 
serious adverse events were reported in Studies 1 and 2, in Study 3 one subject had a serious adverse 
event (coronary artery disease requiring hospitalization), which was unrelated to study treatment. 
Safety analysis was not performed for the pooled analysis. 
 
Discussion 
These three studies were compared using a NMA technique applied to pooled data. Compared to 
ANOVA and meta-analysis techniques, NMAs are recent developments in the statistical arena. 
ANOVA has been used since 1918 [15] and meta-analyses since at least 1976 [16]. These are the 
methods of choice to investigate head-to-head (direct) comparisons. NMA began in 1997, pioneered 
by Bucher [17] who introduced the idea of indirect comparisons that obtain treatment effects across 
studies using a treatment that links the studies together (e.g., A vs B and B vs C leads to A vs C via 
the commonality B). These led into NMA as a combination of direct and indirect treatment 
comparisons [18]. NMAs are not common in the oral health care arena, and though they are used 
frequently by the Cochrane collaboration [e.g., 19], they are rare among in situ studies. As this current 
group of studies were all conducted using the same methodology and at the same study site, this 
makes the NMA technique an ideal methodology to investigate the comparative efficacy of the eight 
investigation dentifrices across three studies linking to common controls. Overall, the network pooled 
across the three studies is fairly well connected but at one third of the full optimum. Two treatments 
(carbomer and 675 NaF) were present in all three studies and act as good reference points across the 
studies. Furthermore, the SMHR and EFU results from the individual studies and when pooled from 
the dentifrices investigated in this pooled analysis are very consistent (Figures 7 and 12, respectively). 
It’s worth noting that the individual study EFU values are arithmetic means, while the values from the 
pooled analysis are from back-transformed log EFU values, which explains why they are generally 
slightly lower (Figure 12). 
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The primary objective of this current pooled analysis of three in situ clinical trials investigating 
remineralization of enamel caries lesions (SMHR) and uptake of fluoride (EFU) was to investigate the 
effect of each treatment compared with a NaF dentifrice containing carbomer and silica and a dose-
response control dentifrice (675F-NaF). For both measures, a dose-response was shown between a 
number of the dentifrices with higher levels of fluoride (1400–1450 ppm) and those with medium 
levels (675 ppm) or no fluoride. Therefore, the present model can be considered of clinical relevance 
as it matches findings from randomized clinical caries trials, which have shown that higher fluoride 
concentrations provide greater anticaries benefits [19].  
Prior research by some of the current authors suggested carbomer may enhance fluoride delivery [23], 
hence the hypothesis that the addition of carbomer to a NaF dentifrice would result in improved 
anticaries efficacy. This, however, was not shown by the pooled analysis to translate to the in situ 
situation, which is often more complex than can be modeled in vitro. While the NaF/carb/silica 
dentifrice was significantly different from the NaF+SnF2/silica/HMP and NaF+MFP/dical dentifrices, 
and additionally from the NaF+MFP/chalk dentifrice for EFU, it was no different from the NaF/silica 
and AmF/silica dentifrices on either measure. These findings also highlight the persistent disconnect 
between laboratory, in situ, and clinical research and that in vitro models alone should be used with 
caution to determine the possible clinical efficacy of new ingredients included in formulations for 
functional benefits. 
There was a mixed picture of efficacy when comparing between the marketed fluoride dentifrices. 
The pooled analysis showed that NaF and AmF dentifrices in general provided greater cariostatic 
benefits than those containing primarily MFP or SnF2 (with NaF also present). The reason for the 
varied performance of fluoride dentifrices of similar fluoride concentration can be manifold. MFP 
dentifrices were considered inferior to their NaF counterparts in a review of the available clinical data 
in 1993 [24]; however, a more recent study found opposite results when comparing a NaF positive 
control dentifrice with two MFP dentifrices formulated with 1.5% arginine in either a di-calcium 
phosphate or calcium carbonate base [25]. This finding was attributed to the arginine and not the 
different fluoride salts.  
Also of interest is that a marketed product (NaF+SnF2/silica/HMP) with an active excipient, 
hexametaphosphate (HMP), performed significantly lower for both SMHR and EFU than all other 
active treatments including the intermediate fluoride dentifrice (675F-NaF). HMP is added for its anti-
calculus and stain-removing cosmetic benefits. This finding is in contrast to an earlier in situ study 
which reported that HMP did not interfere with the anticaries activity of SnF2 [26], and a clinical 
caries study that found the SnF2/HMP combination to be more effective in reducing caries than the 
NaF positive control [27]. However, it is difficult to determine how the formulation of the marketed 
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product that was tested in the current study would compare to the dual-phase experimental prototypes 
tested in these earlier studies. Within the limitations of the study, our findings suggest that fluoride 
source per se is not the ultimate determinant of dentifrice efficacy, as formulation excipients often 
interfere with fluoride efficacy, either by, for example, lowering fluoride bioavailability or by 
providing cariostatic benefits in their own right. The in situ model used to generate the data for the 
pooled analysis is a remineralization-biased model and suffers the limitations that all models have to 
one degree or another. The model measured the treatment effect on a surface-softened lesion, which is 
the initial stage of the caries process, and thus only permits extrapolation of the effect on preventing 
progression to a more advanced stage of caries (cavitation).     
In conclusion, the present pooled analysis using an NMA technique of three independently conducted 
in situ caries studies has shown that commercially available dentifrices vary in their ability to 
fluoridate and remineralize early carious lesions. Dentifrices containing NaF or AmF as the sole 
fluoride source provided the greatest cariostatic benefits, whereas the addition of carbomer did not 
improve nor diminish fluoride efficacy. While some of the observed differences between dentifrices 
can be attributed to the type of fluoride salts, the effect of excipients cannot be ruled out. Study 
products were generally well-tolerated. 
 
Acknowledgements 
We acknowledge and thank the many subjects that participated in these studies, without their 
conscientious participation, these studies would not be possible. We also thank the clinical and 
laboratory staff of the Oral Health Research Institute for the dedication and hard work in conducting 
high quality research, in particular Sue Kelly who was the study manager. We would like to thank 
Eleanor Roberts, Beeline Science Communications, Ltd., funded by GSK Consumer Healthcare, for 
writing support and Ritu Karwal, previously of GSK Consumer Healthcare, for help with study design. 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
13 
 
References 
1. J.D.B. Featherstone, Discussion of session II: Fluoride and the caries process. In: Proceedings 
of a Joint IADR/ORCA International Symposium on Fluorides: Mechanisms of Action and 
Recommendations for Use, 1989, J. Dent. Res. 69 (Spec Iss) (1990) 634–636. 
2. H.C. Margolis, E.C. Moreno, Physicochemical perspectives on the cariostatic mechanisms of 
systemic and topical fluorides, J. Dent. Res. 69 (Spec Iss) (1990) 606–613. 
3. D.T. Zero, In situ caries models, Adv. Dent. Res. 9 (1995) 214–230. 
4. J.P. Pessan, K.J. Toumba, M.A.R. Buzalaf, Topical use of fluorides for caries control, 
Monogr. Oral Sci. 22 (2011) 115–132. 
5. M.F. Johnson, Comparative efficacy of NaF and SMFP dentifrices in caries prevention: a 
meta-analytic overview, Caries Res. 27 (1993) 328–336. 
6. H.M. Proskin, A.R. Volpe, Comparison of the anticaries efficacy of dentifrices containing 
fluoride as sodium fluoride or sodium monofluorophosphate, Am, J, Dent, 8 (1995) 51–58. 
7. T. Koulourides, P. Phantumvanit, E.C. Munksgaard, T. Housch, An intraoral model used for 
studies of fluoride incorporation in enamel, J. Oral. Pathol. 3 (1974) 185–195. 
8. D.T. Zero, J.D.B. Featherstone, J. Fu, A.L. Hayes, G.L. Vogel, Response of a 
de/remineralization in situ caries model to fluoride toothpaste, Caries Res. 28 (1994) 208, 
Abstract 99. 
9. D.T. Zero, J.Z. Zhang, D.S. Harper, M. Wu, S. Kelly, J. Waskow, M. Hoffman, The 
remineralizing effect of an essential oil fluoride mouthrinse in an intraoral caries test, JADA 
135 (2004) 231–237. 
10. T.B.F.M. Gelhard, J.M. ten Cate, J. Arends, Rehardening of artificial enamel lesions in vivo, 
Caries Res. 13 (1979) 80–83. 
11. R.E. Corpron, F.G. More, Clark JW, Korytnicki D, Kowalski CJ, In vivo remineralization of 
artificial enamel lesions by a fluoride toothpaste or mouthrinse, Caries Res. 1986;20:48–55. 
12. J.A. Buskes, K.M. deJosselin, E. deJong, J. Christoffersen, J. Arends, Microradiographic 
study on the demineralization of thick enamel sections: a constant composition study, Caries 
Res. 21 (1987) 15–21. 
13. E.I.F. Pearce, D.G.A. Nelson, In vivo comparison of caries inhibition by a plaque mineral 
enriching mouthrinse and a fluoride toothpaste, Caries Res. 22 (1988) 362–370. 
14. D.T. Zero, J. Fu, K.M. Anne, S. Cassata, S.M. McCormack, L.M. Gwinner, An improved 
intraoral enamel demineralization test model for the study of dental caries, J. Dent. Res. 71 
(Spec Iss) (1992) 871–878. 
15. R.A. Fisher, The correlation between relatives on the supposition of Mendelian inheritance, 
Phil. Trans. Royal Soc. Edin. 52 (1918) 399–433. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
14 
 
16. G.V. Glass, Primary, secondary, and meta-analysis of research, Educ. Researcher 5 (1976) 3–
8. 
17. H.C. Bucher, G.H. Guyatt, L.E. Griffith, S.D. Walter, The results of direct and indirect 
treatment comparisons in meta-analysis of randomized controlled trials, J. Clin. Epidemiol.  
50 (1997) 683–691. 
18. G. Lu, A.E. Ades, Combination of direct and indirect evidence in mixed treatment 
comparisons. Stat. Med., 23 (2004) 3105–3124.  
19. T.  Walsh, H.V. Worthington, A.M. Glenny, P. Appelbe, V.C. Marinho, X. Shi, Fluoride 
toothpastes of different concentrations for preventing dental caries in children and 
adolescents, Cochrane Database Syst. Rev. 1 (2010) CD007868.  
20. D.T. Zero, I. Rahbek, J. Fu, H.M. Proskin, J.D.B. Featherstone, Comparison of the iodide 
permeability test, surface microhardness test and mineral dissolution of bovine enamel 
following acid challenge, Caries Res. 24 (1990) 181–188. 
21. D.J. White, Reactivity of fluoride dentifrices with artificial caries. II Effect of subsurface 
lesions: F uptake, F distribution, surface hardening and remineralization, Caries Res. 22 
(1988) 27–36. 
22. N.Y. Sakkab, W.A. Cilley, J.P. Haberman, Fluoride in deciduous teeth from an anti-caries 
clinical study, J. Dent. Res. 63 (1984) 1201–1205. 
23. A. Butler, E.E. Newby, F. Lippert, Meta analysis comparison of products across different 
laboratory models, J. Dent. Res. 97 (2009) Spec Iss A, Abstract 2948.  
24. G.K. Stookey, P.F. DePaola, J.D. Featherstone, O. Fejerskov, I.J. Möller, S. Rotberg, K.W. 
Stephen, J.S. Wefel, A critical review of the relative anticaries efficacy of sodium fluoride 
and sodium monofluorophosphate dentifrices, Caries Res. 27 (1993) 337–360. 
25. P. Kraivaphan, C. Amornchat, T. Triratana, L.R. Mateo, R. Ellwood, D. Cummins, W. 
DeVizio, Y. Zhang, Two-year caries clinical study of the efficacy of novel dentifrices 
containing 1.5% arginine, an insoluble calcium compound and 1,450 ppm fluoride, Caries 
Res. 47 (2013) 582–590. 
26. J.S. Wefel, C.M. Stanford, D.K. Ament, M.M. Hogan, J.D. Harless, A.M. Pfarrer, L.L. 
Ramsey, M.S. Leusch, A.R. Biesbrock, In situ evaluation of sodium hexametaphosphate-
containing dentifrices, Caries Res. 36 (2002) 122–128. 
27. G.K. Stookey, M.S. Mau, R.L. Isaacs, C. Gonzalez-Gierbolini, R.D. Bartizek, A.R. 
Biesbrock, The relative anticaries effectiveness of three fluoride-containing dentifrices in 
Puerto Rico, Caries Res. 38 (2004) 542–550. 
 
AC
CE
P
ED
 M
AN
US
CR
IPT
15 
 
Table 1. Study test dentifrices 
        Dentifrice Name 
Fluoride Source and Concentration 
Formulation Details  
(Abrasive; surfactant;  
viscosity and rheology modifiers [gums only]) 
Study No 
Individual Study 
Pooled 
Analysis 
1 2 3 
NaF/carb/silica* Same NaF: 1426–1450 ppm F Silica; SLS; carrageenan, xanthan gum, carbomer1 x x x 
NaF/silica** Same NaF: 1400 ppm F Silica; SLS; carrageenan, xanthan gum x   
NaF+MFP/chalk*** Same NaF, MFP: 1450 ppm F Calcium carbonate; SLS; cellulose gum x   
NaF+MFP/dical† Same NaF (450 ppm F), MFP (1000 ppm F): 1450 ppm F  Dicalcium phosphate dihydrate; SLS; cellulose gum  x x 
NaF+SnF2/silica/HMP†† Same NaF (350 ppm F), SnF2 (1100 ppm F): 1450 ppm F Silica; SLS; carrageenan, xanthan gum   x 
AmF/silica††† Same Olaflur: 1400 ppm F Silica; hydroxyethylcellulose  x  
675F-NaF/silicaǂ   675F-NaF NaF: 675 ppm F Silica; SLS; carrageenan, xanthan gum x   
675F-NaF/carb/silicaǂ   675F-NaF NaF: 675 ppm F Silica; SLS; carrageenan, xanthan gum, carbomer  x x 
Placeboǂ   Same 0 ppm F Silica; SLS; carrageenan, xanthan gum x   
Placebo/carbǂ   Placebo 0 ppm F Silica; SLS; carrageenan, xanthan gum, carbomer  x  
1 Acrylates/C10-30 alkyl acrylate crosspolymer 
*Aquafresh® Fresh & Minty Enamelock experimental formulations, GSKCH, Weybridge, UK (formulations were almost identical with minimal differences in fluoride 
concentration); **Aquafresh® Fresh & Minty, GSKCH, Weybridge, UK; ***Signal® Family Protection, Unilever UK Ltd., Leatherhead, UK; †Colgate® Cavity 
Protection, Colgate-Palmolive Co., New York, USA (contributions of fluoride sources to total not disclosed); ††Oral-B® Pro-Expert Clean Mint, Procter & Gamble UK 
Ltd., Weybridge, UK; †††Elmex® Kariesschutz, GABA Schweiz AG, Therwil, Switzerland; ǂAquafresh Fresh & Minty formula base, GSKCH, Weybridge, UK 
NaF=sodium fluoride; Carb=carbomer; MFP=sodium monofluorophosphate; dical=dicalcium phosphate dihydrate; SnF2=stannous fluoride; HMP=sodium 
hexametaphosphate; AmF=amine fluoride; SLS= sodium lauryl sulfate (IUPAC name: sodium dodecyl sulfate) 
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Table 2. Subject disposition (Per Protocol population) 
 
Study 1 
(N=57) 
Study 2 
(N=63) 
Study 3 
(N=82) 
Overall 
(N=202) 
Male       n (%) 23 (40.3) 23 (36.5) 35 (42.7) 81 (40.1) 
Female   n (%) 34 (59.7) 40 (63.5) 47 (57.3) 121 (59.9) 
Mean age (SD) 65.5 (10.32) 67.0 (10.12) 64.0 (8.77) 65.4 (9.69) 
Age range 25–80 37–80 38–80 25–80 
Ethnicity n (%)     
White 31 (54.4) 36 (57.1) 40 (48.7) 107 (53.0) 
Black or African American 26 (45.6) 27 (42.9) 39 (47.6) 92 (45.5) 
Other 0 0 3 (3.7) 3 (1.5) 
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Table 3. Statistical analysis of treatment differences in mean SMHR (%) using pooled data (Per Protocol population) 
Adjusted 
mean (±SE) 
Treatment Differences with 95% CI 
Treatment 
 Comparison  
P-values 
 
NaF/carb/ 
silica 
NaF/silica 
NaF+MFP/ 
dical 
Na+SnF2/ 
silica/HMP 
AmF/silica 
NaF+MFP/ 
chalk 
675F-NaF Placebo 
NaF/carb/ 
silica 
37.61 
(1.507) 
-0.53 
(-6.63, 5.56) 
7.01 
(2.00, 12.02) 
20.41 
(15.79, 25.03) 
-2.17 
(-9.08, 4.73) 
4.40 
(-1.48, 10.30) 
9.29 
(5.14, 13.43) 
24.48 
(19.21, 29.75) 
NaF/silica 1.0000 
38.15 
(2.020) 
7.55 
(0.61, 14.49) 
20.95 
(14.26, 27.64) 
-1.63 
(-10.01, 6.74) 
4.94 
(-1.38, 11.27) 
9.82 
(3.93, 15.72) 
25.02 
(18.36, 31.68) 
NaF+MFP/ 
dical 
0.0007 0.0223 
30.59 
(1.617) 
13.39 
(9.04, 17.74) 
-9.19 
(-16.22, -2.16) 
-2.60 
(-9.36, 4.14) 
2.27 
(-2.19, 6.73) 
17.46 
(11.76, 23.16) 
Na+SnF2/ 
silica/HMP 
<0.0001 <0.0001 <0.0001 
17.19 
(1.480) 
-22.59 
(-29.75, -15.42) 
-16.00 
(-22.50, -9.51) 
-11.12 
(-15.01, -7.23) 
4.06 
(-1.64, 9.78) 
AmF/silica 0.9785 0.9988 0.0022 <0.0001 
39.79 
(2.253) 
6.58 
(-1.63, 14.81) 
11.46 
(4.85, 18.08) 
26.66 
(19.60, 33.71) 
NaF+MFP/ 
chalk 
0.3031 0.2492 0.9354 <0.0001 0.2217 
33.20 
(1.950) 
4.88 
(-0.78, 10.55) 
20.07 
(13.60, 26.54) 
675F-NaF <0.0001 <0.0001 0.7728 <0.0001 <0.0001 0.1487 
28.32 
(1.344) 
15.19 
(10.25, 20.13) 
Placebo <0.0001 <0.0001 <0.0001 0.3672 <0.0001 <0.0001 <0.0001 
13.12 
(1.723) 
On the main diagonal (shaded) are adjusted means with standard errors (±SEs). Above the diagonal are treatment differences with 95% confidence intervals (CIs); below 
the diagonal are P-values for treatment comparisons (significant p-values in bold).   AC
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Table 4. Statistical analysis of treatment differences in mean EFU (µg F/cm2) using pooled data (EFU values given are back-transformed                                
log EFU values; Per Protocol population) 
Adjusted mean  Treatment Differences with 95% CI 
Treatment 
Comparison 
P-values 
 
NaF/carb/ 
silica 
NaF/silica 
NaF+MFP/
dical 
Na+SnF2/ 
silica/HMP 
AmF/silica 
NaF+MFP/ 
chalk 
675F-NaF Placebo 
NaF/carb/ 
silica 
20.92 
1.42 
(-1.94, 5.44) 
6.75 
(4.39, 9.40) 
11.37 
(8.75, 14.36) 
0.04 
(-3.41, 4.18) 
5.76 
(2.19, 10.06) 
6.65 
(4.64, 8.86) 
16.32 
(12.76, 20.61) 
NaF/silica 0.9220 19.50 
5.32 
(1.74, 9.71) 
9.94 
(6.21, 14.56) 
-1.38 
(-5.57, 3.95) 
4.33 
(0.56, 9.00) 
5.22 
(1.95, 9.14) 
14.90 
(10.86, 19.98) 
NaF+MFP/ 
dical 
<0.0001 <0.0001 14.17 
4.62 
(2.71, 6.82) 
-6.70 
(-9.14, -3.76) 
-0.98 
(-3.70, 2.36) 
-0.09 
(-1.72, 1.73) 
9.57 
(6.97, 12.77) 
Na+SnF2/ 
silica/HMP 
<0.0001 <0.0001 <0.0001 9.55 
-11.33 
(-13.13, -9.10) 
-5.61 
(-7.51, -3.24) 
-4.72 
(-5.93, -3.32) 
4.95 
(3.08, 7.28) 
AmF/silica 1.0000 0.9886 <0.0001 <0.0001 20.88 
5.71 
(1.09, 11.65) 
6.60 
(3.16, 10.73) 
16.28 
(11.91, 21.80) 
NaF+MFP/ 
chalk 
<0.0001 0.0098 0.9777 <0.0001 0.0031 15.16 
0.89 
(-1.78, 4.13) 
10.56 
(7.32, 14.68) 
675F-NaF <0.0001 <0.0001 1.0000 <0.0001 <0.0001 0.9799 14.27 
9.67 
(7.20, 12.66) 
Placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 4.60 
On the main diagonal (shaded) are back-transformed adjusted means (geometric means). SEs are not shown due to the antilog transformation of SE not compatible with 
the geometric mean presented. Above the diagonal are back-transformed treatment differences with approximately back-transformed 95% confidence intervals (CIs); 
below the diagonal are P-values for treatment comparisons (significant p-values in bold).   
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Table 5. Treatment-emergent adverse events 
Study 1 
NaF/carb/ 
silica (n=50) 
NaF+MPF/ 
chalk (n=53) 
NaF/silica 
(n=52) 
675F-NaF/silica 
(n=53) 
Placebo 
(n=51) Overall 
n(%) nAE n(%) nAE n(%) nAE n(%) nAE n(%) nAE n(%) nAE 
All AEs 8(16.0) 9 8(15.1) 9 4(7.7) 5 9(17.0) 9 6(11.8) 6 24(42.1) 38 
Oral AEs 5(10.0) 5 5(9.4) 6 2(3.8) 3 6(11.3) 6 3(5.9) 3 17(29.8) 23 
TR-TEAEs 0 0 1(1.9) 1 1(1.9) 2 0 0 0 0 1(1.9) 2 
Oral discomfort 0 0 0 0 1(1.9) 2 0 0 0 0 0 0 
Lip dry 0 0 1(1.9) 1 0 0 0 0 0 0 1(1.9) 1 
Study 2 
NaF/carb/ 
silica (n=57) 
NaF+MPF/ 
dical (n=59) 
AmF/silica 
(n= 57) 
675F-NaF/ 
carb/silica (n=59) 
Placebo/carb 
(n=59) Overall 
n(%) nAE n(%) nAE n(%) nAE n(%) nAE n(%) nAE n(%) nAE 
All AEs 11(19.3) 16 8(13.6) 9 12(21.1) 14 8(13.6) 9 7(11.9) 7 35(53.8) 55 
Oral AEs 5(8.8) 6 2(3.4) 2 3(5.3) 3 1(1.7) 1 3(5.1) 3 13(20.0) 15 
TR-TEAEs 0 0 1(1.7) 1 2(3.5) 2 0 0 1(1.7) 1 4(6.2) 4 
Dry mouth 0 0 1(1.7) 1 1(1.8) 1 0 0 0 0 2(3.1) 2 
Oral mucosal exfoliation 0 0 0 0 0 0 0 0 1(1.7) 1 1(1.5) 1 
Sensitivity of teeth 0 0 0 0 1(1.8) 1 0 0 0 0 1(1.5) 1 
Study 3 
NaF/carb/ 
silica (n=79) 
NaF+MPF/ 
dical (n= 80) 
NaF+SnF2/silica/H
MP (n=80) 
675F-NaF/carb/ 
silica (n=79)  Overall 
n(%) nAE n(%) nAE n(%) nAE n(%) nAE  n(%) nAE 
All AEs 10(12.7) 11 18(22.5) 24 15(18.8) 19 12(15.2) 14  40(48.2) 68 
Oral AEs 6(7.6) 6 8(10.0) 12 9(11.3) 9 8(10.1) 10  27(32.5) 37 
TR-TEAEs 0 0 1(1.3) 3 0 0 0 0  1(1.2) 3 
Burning sensation 0 0 1(1.3) 1 0 0 0 0  1(1.2) 1 
Chapped lips 0 0 1(1.3) 1 0 0 0 0  1(1.2) 1 
Oral discomfort 0 0 1(1.3) 1 0 0 0 0 1(1.2) 1
n(%) = number (percent) of subjects; nAE = number of adverse events; Treatment-related treatment-emergent adverse event (TR-TEAE)AC
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Figure headings and footers 
 
Figure 1. Study flow 
Figure 2. Network diagram of treatments and their connections via the three studies 
Figure 3. Individual study mean SMHR (%; adjusted means ±SE) after 14 days of product use 
Figure 4. Pooled analysis mean SMHR (%; adjusted means ±SE) after 14 days of product use 
Figure 5. SMHR (%) treatment comparisons with NaF/Carb/silica group 
A positive treatment difference suggests a beneficial effect for the first-named treatment. The study 
results are from the individual studies, and not from the pooled analysis. Pooled CIs are adjusted for 
multiple comparisons; individual study CIs are not adjusted. 
Figure 6. SMHR (%) treatment comparisons with the combined 675F-NaF dose response 
control group  
A positive treatment difference suggests a beneficial effect for the first-named treatment. The study 
results are from the individual studies, and not from the pooled analysis. Pooled CIs are adjusted for 
multiple comparisons; individual study CIs are not adjusted. 
Figure 7. Adjusted mean SMHR values from each study and from the pooled analysis 
Data points are offset for clarity. 
Figure 8. Individual study mean EFU (adjusted means, ±SE) after 14 days of product use  
Figure 9. Pooled analysis mean EFU (adjusted means, ±SE) after 14 days of product use  
Figure 10. EFU (µg F/cm2) treatment comparisons with the NaF/Carb/silica group 
A positive treatment difference suggests a beneficial effect for the first named treatment. 
The study results are from the results of the individual study not from the pooled analysis. Pooled CIs 
are adjusted for multiple comparisons; individual study CIs are not adjusted. 
Figure 11. EFU (µg F/cm2) treatment comparisons with the combined 675F-NaF dose response 
control group 
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A positive treatment difference suggests a beneficial effect for the first named treatment. 
The study results are from the results of the individual study not from the pooled analysis. Pooled CIs 
are adjusted for multiple comparisons; individual study CIs are not adjusted. 
Figure 12. Adjusted mean EFU values from each study and from the pooled analysis 
Data points are offset for clarity. Individual study EFU values are arithmetic means; values from the 
pooled analysis are from back-transformed log EFU values. 
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Supplemental Data Tables 
Supplemental Table 1: Percent Surface Microhardness Recovery (%SMHR) and Enamel 
Fluoride Uptake (EFU; adjusted means) 
Study 1 (ITT population) %SMHR (±SE) EFU µg F/cm3 ( ±SE) 
NaF/carb/silica (n=50) 34.62 (2.82) 2499.47 (133) 
NaF/silica (n=52) 36.06 (2.79) 2513.37 (131) 
675F-NaF/silica (n=53) 27.15 (2.75) 1861.80 (130) 
NaF+MFP/chalk (n=53) 31.12 (2.77) 1923.76 (130) 
Placebo (n=51) 11.10 (2.80) 686.18 (132) 
Study 2 (PP population) %SMHR (±SE) EFU µg F/cm3 ( ±SE) 
NaF/carb/silica (n=56) 38.05 (2.52) 2342.35 (123.65) 
675F-NaF/carb/silica (n=59) 29.08 (2.50) 1649.44 (121.93) 
AmF/silica (n=57) 41.06 (2.53) 2305.11 (123.83) 
NaF+MFP/dical (n=58) 33.48 (2.49) 1809.74 (121.83) 
Placebo/carb (n=59) 14.49 (2.48) 462.95 (120.92) 
Study 3 (PP population) %SMHR (±SE) EFU µg F/cm2 ( ±SE) 
NaF/carb/silica (n=78) 40.94 (1.93) 22.33 (0.85) 
NaF+SnF2/silica/HMP (n=79) 17.88 (1.92) 9.13 (0.85) 
NaF+MFP/dical (n=78) 30.19 (1.93) 13.54 (0.85) 
675F-NaF/carb/silica (n=76) 28.74 (1.94) 14.31 (0.86) 
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Supplemental Table 2: Study 1 Percent Surface Microhardness Recovery (%SMHR) and 
Enamel Fluoride Uptake (EFU; adjusted means): Between treatment comparisons  
  Difference 
(Adjusted Mean) [95% CI] 
p-value 
Percentage 
change** 
                               %SMHR* 
NaF/carb/silica vs NaF/silica -1.45 [-6.15, 3.26] 0.5451 -4.0 
675F-NaF/silica  7.47 [2.78, 12.16] 0.0020 27.5 
NaF+MFP/chalk 3.50 [-1.20, 8.19] 0.1433 11.2 
Placebo 23.52 [18.79, 28.25] <0.0001 212.0 
NaF/silica vs 675F-NaF/silica 8.92 [4.24, 13.59] 0.0002 32.8 
NaF+MFP/chalk 4.94 [0.29, 9.59] 0.0373 15.9 
Placebo 24.97 [20.27, 29.66] <0.0001 225.0 
NaF+MFP/chalk vs 675F-NaF/silica 3.98 [-0.66, 8.61] 0.0925 14.6 
Placebo 20.03 [15.35, 24.70] <0.0001 180.5 
     675F-NaF/silica vs    Placebo 16.05 [11.36, 20.74] <0.0001 144.6 
                              EFU (µg F/cm3)* 
NaF/carb/silica vs NaF/silica -13.90 [-322.47, 294.66] 0.9293 -0.6 
675F-NaF/silica 637.67 [330.30, 945.03] <0.0001 34.2 
NaF+MFP/chalk 575.71 [268.24, 883.17] 0.0003 29.9 
Placebo 1813.29 [1503.03, 2123.54] <0.0001 264.3 
NaF/silica vs 675F-NaF/silica 651.57 [346.44, 956.70] <0.0001 35.0 
NaF+MFP/chalk 589.61 [285.31, 893.92] 0.0002 30.6 
Placebo 1827.19 [1519.78, 2134.60] <0.0001 266.3 
NaF+MFP/chalk vs 675F-NaF/silica 61.96 [-241.25, 365.17] 0.6874 3.3 
Placebo 1237.58 [931.46, 1543.70] <0.0001 180.4 
     675F-NaF/silica vs    Placebo 1175.62 [869.15, 1482.10] 0.2432 <0.0001 
*A positive difference favors the first named treatment 
**Second toothpaste used as reference in calculation of % change [(Difference/Reference)*100] 
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Supplemental Table 3: Study 2 Percent Surface Microhardness Recovery (%SMHR) and 
Enamel Fluoride Uptake (EFU; adjusted means): Between treatment comparisons  
  Difference 
(Adjusted Mean) [95% CI] 
p-value 
Percentage 
change** 
                                      %SMHR* 
NaF/carb/silica vs AmF/silica  -3.01 [-7.75, 1.73] 0.2117 -7.3 
675F-NaF/carb/silica 8.96 [4.27, 13.66] 0.0002 30.8 
NaF+MFP/dical 4.57 [-0.11, 9.24] 0.0557 13.6 
Placebo/carb 23.55 18.86, 28.24] <0.0001 162.5 
AmF/silica vs 675F-NaF/carb/silica 11.97 [[7.31, 16.64] <0.0001 41.2 
NaF+MFP/dical 7.58 [2.88, 12.27] 0.0017 22.6 
Placebo/carb 26.56 [21.88, 31.24] <0.0001 183.3 
NaF+MFP/dical vs 675F-NaF/carb/silica 4.40 [-0.23, 9.03] 0.0625 15.1 
Placebo/carb 18.99 [14.36, 23.61] <0.0001 131.0 
 675F-NaF/carb/silica vs    Placebo/carb 14.59 [9.95, 19.23] <0.0001 100.7 
                                       EFU (µg F/cm3)* 
NaF/carb/silica vs AmF/silica  37.24 [-239.62, 314.09] 0.7912 1.6 
675F-NaF/carb/silica 692.91 [418.73, 967.09] <0.0001 42.0 
NaF+MFP/dical 532.61 [259.06, 806.16] 0.0002 29.4 
Placebo/carb 1879.40 [1605.75, 2153.04] <0.0001 406.0 
              AmF/silica vs 675F-NaF/carb/silica 655.67 [382.41, 928.93] <0.0001 39.8 
NaF+MFP/dical 495.38 [221.09, 769.66] 0.0005 27.4 
Placebo/carb 1842.16 [1568.73, 2115.60] <0.0001 397.9 
      NaF+MFP/dical vs 675F-NaF/carb/silica 160.30 [-110.58, 431.18] 0.2448 9.7 
Placebo/carb 1346.79 [1076.46, 1617.11] <0.0001 290.9 
    675F-NaF/carb/silica vs     Placebo/carb 1186.49 [915.38, 1457.60] <0.0001 256.3 
*A positive difference favors the first named treatment 
**Second toothpaste used as reference in calculation of % change [(Difference/Reference)*100] 
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Supplemental Table 4: Study 3 Percent Surface Microhardness Recovery (%SMHR) and 
Enamel Fluoride Uptake (EFU; adjusted means): Between treatment comparisons  
  Difference 
(Adjusted Mean) [95% CI] 
p-value 
Percentage 
change** 
                                              %SMHR* 
NaF/carb/silica vs NaF+SnF2/silica/HMP  10.75 [7.33, 14.17] <0.0001 35.6 
 NaF+MFP/dical  23.06 [19.63, 26.48] <0.0001 128.9 
 675F-NaF/carb/silica 12.20 [8.74, 15.67] <0.0001 42.5 
 NaF+SnF2/silica/HMP vs NaF+MFP/dical 12.31 [8.90, 15.72] <0.0001 68.8 
 675F-NaF/carb/silica 1.46 [-2.00, 4.91] 0.4070 5.1 
           NaF+MFP/dical vs     675F-NaF/carb/silica -10.85 [-14.30, -7.40] <0.0001 -37.8 
                                              EFU (µg F/cm2)* 
NaF/carb/silica vs NaF+SnF2/silica/HMP  8.79 [7.04, 10.55] <0.0001 65.0 
 NaF+MFP/dical  13.21 [11.46, 14.96] <0.0001 144.7 
 675F-NaF/carb/silica 8.03 [6.25, 9.80] <0.0001 56.1 
  NaF+SnF2/silica/HMP vs NaF+MFP/dical 4.41 [2.66, 6.16] <0.0001 48.4 
 675F-NaF/carb/silica -0.77 [-2.54, 1.00] 0.3942 -5.4 
            NaF+MFP/dical vs    675F-NaF/carb/silica -5.18 [-6.95, -3.41] <0.0001 -36.2 
*A positive difference favors the first named treatment 
**Second toothpaste used as reference in calculation of % change [(Difference/Reference)*100] 
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